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The t(8;21) and t(16;21) that are associated with acute
myeloid leukaemia disrupt two closely related genes
termed Myeloid Translocation Genes 8 (MTG8) and 16
(MTG16), respectively. Many of the transcription factors
that recruit Mtg16 regulate haematopoietic stem and pro-
genitor cell functions and are required to maintain stem
cell self-renewal potential. Accordingly, we found that
Mtg16-null bone marrow (BM) failed in BM transplant
assays. Moreover, when removed from the animal,
Mtg16-deficient stem cells continued to show defects in
stem cell self-renewal assays, suggesting a requirement for
Mtg16 in this process. Gene expression analysis indicated
that Mtg16 was required to suppress the expression of
several key cell-cycle regulators including E2F2, and
chromatin immunoprecipitation assays detected Mtg16
near an E2A binding site within the first intron of E2F2.
BrdU incorporation assays indicated that in the absence of
Mtg16 more long-term stem cells were in the S phase, even
after competitive BM transplantation where normal stem
and progenitor cells are present, suggesting that Mtg16
plays a role in the maintenance of stem cell quiescence.
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Introduction
Non-random, somatically acquired, chromosomal transloca-
tions are commonly associated with the development of acute
leukaemia and affect genes that control cell proliferation,
differentiation, survival, and lineage decisions that affect
stem cell self-renewal and progenitor cell differentiation
(Hope et al, 2003). While translocations can cause the over-
expression of dominantly acting oncogenes such as BCL2 or
c-MYC (Dalla-Favera et al, 1982; Graninger et al, 1987), the
majority of the fusion proteins that are created in the myeloid
lineage create weak oncogenes that do not have a single
dominant phenotype. As such, the genes that are disrupted by
these translocations have been extensively studied in order to
understand the function of the translocation fusion proteins.
The t(8;21) and t(16;21) target two closely related Myeloid
Translocation Gene (MTG) family members, MTG8 (also
known as RUNX1T1 or ETO) and MTG16 (also known as
CBFA2T3 or ETO2), respectively. The t(8;21) is associated
with 12–15% of de-novo acute myeloid leukaemia (AML)
cases, while the t(16;21) is more rare and associated with
therapy-related AML (Miyoshi et al, 1991; Erickson et al,
1992; Gamou et al, 1998; Davis et al, 1999). Both of these
translocations create fusion proteins containing the DNA
binding domain of RUNX1 (formerly called AML1) fused to
nearly full-length of MTG8 or MTG16 (Miyoshi et al, 1991,
1993; Erickson et al, 1992; Gamou et al, 1998).
These fusion proteins have the capacity to repress genes
containing a RUNX1 DNA binding site such as p14ARF
(Cdkn2a isoform4), Neurofibromatosis-1 (Nf-1), PU.1 (Spi1),
and C/EBPa (Cebpa) (Pabst et al, 2001; Linggi et al, 2002;
Vangala et al, 2003; Yang et al, 2005). While repression of
tumour suppressor genes is an attractive hypothesis for how
these fusion proteins trigger leukaemia, these translocations
also disrupt one allele of RUNX1 and either MTG8 or MTG16,
suggesting that haploinsufficiency or impairment of RUNX1
or MTG8/MTG16 may also contribute to leukaemogenesis.
For RUNX1 and its closely related family member RUNX3,
mouse models with deletions of these genes have supported
this hypothesis (Song et al, 1999; Li et al, 2002; Silva et al,
2003). For the MTG family, possible inactivating mutations
have been identified in MTG8 in colon, lung, and breast
cancer (including a frame shift mutation), whereas MTG16
mutations were found in ovarian cancer (Wood et al, 2007;
Kan et al, 2010). MTG family members also have the ability to
form oligomers, and the fusion proteins associated with
leukaemia bind to the wild-type MTGs that remain
(Kitabayashi et al, 1998; Zhang et al, 2004; Liu et al, 2006).
These data suggest that loss of function of MTG proteins
could contribute to leukaemogenesis; yet, the mechanism by
which this might occur remains obscure.
The ability of the t(8;21) fusion protein to repress trans-
cription suggested that the MTG family members act as
transcriptional co-repressors. This repression is mediated by
the recruitment of the mSin3 and N-CoR/SMRT co-repressors
and class I histone deacetylases (Gelmetti et al, 1998;
Lutterbach et al, 1998; Wang et al, 1998; Amann et al,
2001; Hildebrand et al, 2001). As expected for transcriptional
co-repressors, MTG family members are recruited by many
site-specific DNA binding proteins, including Gfi1, Gfi1B,
TAL1/SCL, the ‘E proteins’ E2A and HEB, BTB-POZ domain
factors BCL6 and PLZF, and mediators of Wnt and Notch
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signalling (TCF4 and CSL) (Melnick et al, 2000; McGhee et al,
2003; Chevallier et al, 2004; Zhang et al, 2004; Schuh et al,
2005; Goardon et al, 2006; Moore et al, 2008; Salat et al, 2008;
Engel et al, 2010; Soler et al, 2010). E proteins may play key
roles as the association is robust and a point mutant of
Mtg16/Eto2 lacking the ability to regulate E2A or HEB failed
to complement Mtg16/-associated defects in T-cell differ-
entiation (Hunt et al, 2011). Thus, MTG family members play
a pivotal function during haematopoiesis to link DNA binding
transcription factors to chromatin modifying enzymes to
influence gene expression.
The balance between haematopoietic stem cell (HSC)
differentiation and self-renewal must be maintained to ensure
homeostasis, long-term stem cell viability, and suppress
cancer formation (Santaguida et al, 2009). Thus, the discov-
ery of factors that control these processes in HSCs is impor-
tant in terms of tumourigenesis and for their use in clinical
applications such as haematopoietic cell transplantation. In
addition, understanding the role of regulatory factors in HSC
function can be applied to other organ systems (Shizuru et al,
2005). Interestingly, the engineered inactivation of many
transcription factors that recruit MTG family members iden-
tified them as key regulators of stem cell functions and
lineage allocation in mice. In several instances, these pheno-
types were related to inappropriate cycling of the lineage-
negative, Sca1þ , c-Kitþ (LSK) stem/progenitor cells (e.g.,
Gfi1, E2A), which caused depletion of stem cell pools or non-
competitive long-term stem cells (Hock et al, 2004; Zeng et al,
2004; Semerad et al, 2009). These data suggest that MTG
family members might contribute to stem cell functions.
Mtg16 is the dominant MTG family member expressed in
haematopoietic stem and early progenitor cells and micro-
array profiling of normal and leukaemic stem cells suggests
that Mtg16 is expressed in these cells (Lindberg et al, 2005;
Deneault et al, 2009). Moreover, MTG family members ap-
pear to act through E proteins that are critical for stem cell
homeostasis. Here, we demonstrate that inactivation of
Mtg16 caused a reduction in HSC pools that could be traced
to the hyperactive cycling of stem cells (lineage-negative,
Sca1þ/c-Kitþ , LSK cells, LSK/Flt3, and LSK/CD150þ/
CD48). This uncontrolled cycling led to stem cell exhaustion
after serial competitive bone marrow (BM) transplantation.
The increased cycling was associated with the inappropriate
expression of E2F2, Cyclin D1 (Ccnd1), and N-Myc (Mycn)
and was evident even after competitive BM transplantation,
suggesting a cell intrinsic defect. Chromatin immunoprecipi-
tation (ChIP) directly linked Mtg16/Eto2 to an enhancer in
the first intron of E2F2, which is a putative target for regula-
tion by E proteins. Thus, Mtg16 plays a key role in suppres-
sing the entry of HSCs into the cell cycle.
Results
Defects in Mtg16-null HSCs
Mtg16/ mice show only modest haematopoietic defects, but
when challenged they lacked the ability to respond to erythro-
poietic stress (Chyla et al, 2008). These results, along with the
linkage of MTG family members to Wnt and Notch signalling,
prompted us to carefully examine the haematopoietic stem and
progenitor cell compartments in Mtg16/ mice. We used flow
cytometry to identify lineage-negative, Sca1þ , c-Kitþ (LSK)
cells, which represent stem and early progenitor cells. These
cells were reduced by roughly two-fold in Mtg16/ mice and
when these cells were further divided based on Flt3 expression
to focus in on the stem cell population, the LSK/Flt3 cells
were also reduced by nearly two-fold (Figure 1A–C). To
confirm the reduction in the stem cell population, we further
fractionated the LSK/Flt3 cells with the signalling lymphocyte
attractant molecule (SLAM) markers CD150 and CD48, which
greatly enriches for long-term repopulating HSCs (LT-HSC)
(Kiel et al, 2005). The LSK/Flt3/CD150þ/CD48 fraction of
cells (LT-HSC) was also reduced by slightly 42-fold in the
Mtg16/ mice (Figure 1D).
Next, we used BM transplantation assays to assess stem
cell functions. While injection of only 200 000 wild-type cells
were sufficient to provide radioprotection and yielded 100%
survival, injection of 200 000 Mtg16-deficient cells failed to
reconstitute the marrow with all mice succumbing within 30
days. Injection of one million cells only extended the survival
to a maximum of 52 days, suggesting that the stem cells were
defective in repopulating the marrow (Figure 2A). However,
the impaired erythroid progenitor cell function observed
previously could also contribute to this phenotype.
Therefore, we performed competitive BM transplants to
assess stem cell function in the context of wild-type progeni-
tor cells using 10% wild-type (CD45.1þ ) cells to provide
radioprotection along with 90% Mtg16/ (CD45.2þ ) BM
cells. Given that there were only about 25% of the normal
complement of stem cells (Figure 1), using a 9:1 ratio of null
to wild-type cells equates to using roughly two-fold more null
stem cells than wild type. Within 7 weeks of transplant there
were already substantial reductions in the number of Mtg16/
cells in the peripheral blood with only 25–30% CD45.2þ cells
present (Figure 2B). By 13 weeks post transplant, when the
peripheral blood cells are derived from the long-term stem cells,
the percentage of CD45.2þ cells had dropped to o20%. These
cells continued to erode over time falling to nearly 10% after 1
year while control CD45.2þ cells maintained a level of at least
90% (Figure 2B).
Although the analysis of peripheral blood suggested dra-
matic defects in Mtg16/ stem cells, excluding erythrocytes,
the peripheral blood is mostly composed of B and T cells.
Given that Mtg16/ mice have decreased numbers of B cells
under homeostasis (Chyla et al, 2008) and Mtg16 is required
for the differentiation of T cells (Hunt et al, 2011), we used
flow cytometry analysis to examine the BM 12 weeks after
competitive transplantation. We found a 2–3-fold reduction in
CD45.2þ cells in the total BM (Figure 2C and D), whereas
only half this number of cells (about 20%) made it into the
peripheral blood (Figure 2B). A further breakdown of the
contribution of CD45.2þ cells in the BM showed loss of
lymphoid cells and a skewing of the Mtg16/ cells towards
the myeloid lineage with over 80% of the Mtg16/ cells
being Gr1þ and/or Mac1þ (Supplementary Figure S1A and
B), which is an exaggeration of the phenotype observed at
homeostasis (Chyla et al, 2008).
We also examined the LSK and LSK/Flt3 cells in the BM to
determine the number of CD45.2þ cells that remained at 12
weeks post transplant (Figure 2D; Supplementary Figure S2).
There was a 2.8-fold reduction in CD45.2þ LSK cells, and a 3-
fold reduction in CD45.2þ LSK/Flt3 stem cells that derived
from the Mtg16/ mice (Figure 2D; Supplementary Figure S2
for FACS plots). Given that we started with roughly two times
more stem cells by using a 9:1 ratio of null to wild-type cells
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(starting material contains 25% of the normal complement of
LSK/Flt3/CD150þ/CD48 cells, Figure 1, multiplied by a 9:1
ratio), there was an overall 5–6-fold defect in stem cell activity.
Next, we performed a secondary transplant to further examine
Mtg16/ stem cell functions. Six weeks after transplanting
irradiated recipient mice with BM from primary transplants
that contained from 25 to 45% CD45.2þ BM (Mtg16/), there
was a dramatic loss of Mtg16/ cells in the peripheral blood
and flow cytometry analysis of the BM of these mice indicated
a near complete loss of Mtg16/ LSK and LSK/Flt3 cells
(Figure 3; Supplementary Figure S3 for FACS plots). By con-
trast, control mice contained 80–90% CD45.2þ cells in the BM
(Figure 3). Thus, Mtg16 is required to maintain stem cells,
even when normal progenitor cells are present, suggesting a
stem cell intrinsic defect.
To ensure that the observed stem cell defects were not due
to contributions from the BM stroma, we assessed the
expression of Mtg16 in adult BM stromal fibroblasts as
compared with murine erythroleukaemia (MEL) cells and
murine embryonic fibroblasts (MEFs). Quantitative real-
time PCR showed that Mtg16 was expressed at much lower
levels in adult BM stromal cells or MEFs, as compared with
its closely related family member, Mtgr1 (CBFA2T2), which
was robustly expressed in both cell types, whereas Mtg8/ETO
(RUNX1T1) was robustly expressed in MEFs but not in adult
BM fibroblasts (Supplementary Figure S4). The low levels of
Mtg16 mRNA were confirmed by a concordant lack of readily
detectable Mtg16 protein in the BM stromal cells (data not
shown). In addition, we did not observe an increase in stem




































































































































































Figure 1 Inactivation of Mtg16 decreases HSC numbers. Quantification of flow cytometry of whole bone marrow cells. Lineage-negative cells
were gated (A) and further analysed using anti-Sca-1 and anti-c-Kit (B; LSK). The LSK cells were further fractionated using anti-Flt3 to obtain
the LSK/Flt3 (C), which was further divided using anti-CD150/anti-CD48 to identify the LSK/Flt3/CD150þ/CD48 populations (D).
Quantification of each of these populations is calculated for the number of cells per leg (femurþ tibia) and is shown to the right of each dot plot
(wild type n¼ 5, empty bars; Mtg16-null n¼ 5, full bars). Data are expressed as mean±the standard error of the mean (s.e.m.). An unpaired
two-tailed t-test indicated that the changes observed in the number of cells were significant (***Pp0.0001).
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suggesting that the null stem cells were maintained within
the BM niche (data not shown).
Mtg16/ cells home to the BM
To ensure that this defect was not simply due to a failure of
the stem cells to home to the marrow, we labelled BM cells
ex vivo with the vital dye carboxyfluorescein succinimidyl
ester (CFSE) before injecting these cells into the tail vein of
mice. Sixteen hours later, the BM of these mice was analysed
by flow cytometry and the number of cells positive for CFSE
was quantified (Figure 4A). A similar number of null cells as
compared with wild-type controls were found in the BM.
Given that the CFSE experiment assessed whole BM, we
further examined the homing of stem and progenitor cells
by performing methylcellulose colony formation assays 16 h
after BM transplantation and calculating the percentage of
stem/progenitor cells that correctly homed to the BM
(Figure 4B). The small changes observed were within the
statistical error, indicating that immature Mtg16/ cells
homed correctly to the marrow (note that irradiated controls
yielded only 5–6 colonies compared with 50–75 colonies from
injected mice, and this background level was removed in the
calculation of the percent of homing).
Mtg16 deficiency affects stem cell self-renewal
The haematopoietic defects found in the LSK/Flt3 and LSK/
CD48/CD150þ stem cell compartments (Figure 1) and
identified in BM transplantation assays, suggested that
Mtg16 was required for stem cell self-renewal (Figure 3). To
further define the defect, we used in-vitro analyses of stem
cell functions. First, we serially cultured BM cells in methyl-
cellulose. Stem cells from control mice were able to form
colonies through three consecutive rounds of culture in
methylcellulose containing IL6, stem cell factor (SCF), ery-
thropoietin, and IL3, but yielded only about 15% of the
number of colonies after the fourth culture (Figure 5A). By
contrast, Mtg16-null cells displayed a four-fold reduction in
replating ability after the second round of culture (Figure 5A)
and were essentially exhausted by the fourth culture. We
extended these results by testing the function of Mtg16-null
stem cells in a long-term culture-initiating cell (LTC-IC) assay,
which tests long-term stem cell function in a controlled in-
vitro environment (Miller et al, 2008). The initial cultures of
3000 Mtg16-null lineage-negative cells contained the same
number of CFU-C-producing cells as 3000 wild-type lineage-
negative cells. The same was true after 1 week in culture
(Figure 5B). However, by the second week of culture, the
number of CFU-C-producing cells present in the Mtg16-null
cultures was drastically reduced compared with the wild-type
cultures, and almost completely absent after just 3 weeks in
culture (Figure 5B), suggesting a loss of self-renewal.
Mechanistically, Mtg16 can be recruited by many tran-
scription factors that regulate stem cell function including
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Figure 2 Inactivation of Mtg16 disrupts HSC functions. (A) Survival curves of a representative transplant experiment using 200 000 wild-type
bone marrow (BM) cells (open circles), 200 000 Mtg16-null BM cells (open boxes), or 1000 000 Mtg16-null bone marrow cells (filled
diamonds). (B) Competitive repopulation assay where 90% control (empty bars) or Mtg16-null (filled bars) CD45.2þ BM cells were co-injected
with 10% wild-type CD45.1þ cells. The contribution of each population to long-term reconstitution of the BM was assessed by flow cytometry
using anti-CD45.1 and anti-CD45.2 to enumerate cells in the peripheral blood. Data are expressed as mean±s.e.m. at different times after
transplantation. An unpaired two-tailed t-test indicated these differences (marked by an *) were statistically significant at all time points after
transplantation (Po0.0001; n¼ 5). (C) Flow cytometry analysis of whole BM to determine the percentage of CD45.2 that had repopulated the
bone marrow 12 weeks after a competitive repopulation assay. A representative plot from an experiment performed in triplicate that is
consistent with other biological replicates is shown. (D) Graphical representation of the quantification of CD45.2 cells residing in the BM and
LSK or LSK/Flt3 compartments 12 weeks after competitive BM transplantation.
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of Wnt and Notch signalling (TCF4 and CSL) (Melnick et al,
2000; McGhee et al, 2003; Chevallier et al, 2004; Zhang et al,
2004; Schuh et al, 2005; Goardon et al, 2006; Moore et al,
2008; Salat et al, 2008; Engel et al, 2010). To begin to address
which of these pathways might be critical to Mtg16-depen-
dent stem cell functions, we re-expressed Mtg16, or a point
mutant of Mtg16 that fails to suppress E protein-dependent
transcription (F210A; R220A is a control mutation) (Hunt
et al, 2011) in null BM cells and performed LTC-IC assays
(Figure 5C; see Supplementary Figure S5 for expression
controls). Wild-type Mtg16 and the R220A mutant comple-
mented the LTC-IC defect, further suggesting that these
defects were not due to the in vivo microenvironment.
However, the F210A point mutant that disrupts one of the
two contact sites for binding to E proteins (Plevin et al, 2006;
Guo et al, 2009) only partially complemented this defect.
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Figure 5 Inactivation of Mtg16 impairs stem cell self-renewal.
(A) Graphical representation of the numbers of methylcellulose
colonies formed during serial replating assays where 2104 cells
were plated every 7 days for 4 weeks (wild type, empty bars; Mtg16-
null, full bars). Data are expressed as mean±s.e.m. An unpaired
two-tailed t-test indicated these differences were statistically sig-
nificant (marked by an *; first, P¼ 0.03; second, P¼ 0.01; third,
Po0.001; n¼ 4). Representative results from an experiment done in
duplicate that are consistent with other biological replicates are
shown. (B) Graphical representation of the numbers of methylcel-
lulose colonies formed at the indicated times from LTC-IC cultures
of wild-type (open bars) and Mtg16-null (full bars) bone marrow
cells. Data are expressed as mean±s.e.m. An unpaired two-tailed
t-test indicated the difference at week 2 and week 3 after culture
(marked with an *) was statistically significant (Po0.05; n¼ 4).
Representative results from three separate experiments are shown.
(C) Mtg16 re-expression, but not Mtg16-F210A, complements the
LTC-IC defect in Mtg16-null bone marrow cells. Schematic diagram
shows the positions of the F210A (blocks Mtg8 binding to HEB and
Mtg16 suppression of E protein-dependent transcription) and
R220A (control mutation that does not affect E protein binding in
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Figure 3 Serial transplantation reveals requirements for Mtg16 in
the maintenance of stem cells. (A) Flow cytometry analysis of
whole bone marrow to determine the percentage of CD45.2 that
had repopulated the bone marrow (BM) 6 weeks after secondary
bone marrow transplantation from an initial competitive repopula-
tion assay. A representative plot from an experiment performed in
triplicate that is consistent with other biological replicates is shown.
(B) Graphical representation of the quantification of CD45.2 cells
residing in the BM and LSK or LSK/Flt3 compartments 6 weeks
















































Figure 4 Mtg16/ cells home to the bone marrow. (A) Bone
marrow from control wild-type and Mtg16/ mice was stained
with CFSE and injected into lethally irradiated recipient mice. The
bone marrow was analysed by flow cytometry to identify CFSE-
labelled cells. (B) Representative graph of the number of colony-
forming cells that homed to the bone marrow 16 h after injection
into lethally irradiated recipient mice.
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The inactivation of Mtg16 alters the expression of
cell-cycle control genes
Given that Mtg16 appears to act as a transcriptional
co-repressor, we compared gene expression in control and
Mtg16-null lineage-negative, Sca1þ , c-Kitþ cells using cDNA
microarray analysis. Because these cells are rare, LSK cells
were sorted and pooled from 10 wild-type and 10 Mtg16-null
mice and the experiment was performed using biological
triplicates. We consistently observed changes in genes that
function in haematopoietic differentiation, including, 4–6-
fold higher levels of Id1 and Id2, whose overexpression
caused skewing of lineage allocation towards myelopoiesis
and away from lymphopoiesis (Buitenhuis et al, 2005). The
genes showing changes were categorized based on biological
pathways or biological processes using the Panther classifica-
tion system and genes that are associated with cell-cycle
control, or the transition out of quiescence, were upregulated
including Fos, E2F2, Raf1, Cyclin D1, Cdk2, and N-Myc
(P-value of 0.05 for cell-cycle classification; representative
cell-cycle control genes are shown in Figure 6A, see
Supplementary Tables S1 and S2 for the lists of genes two-
fold up or down) (Thomas et al, 2003). The microarray data
were confirmed using selected genes whose expression was
altered in the arrays, including Id1, Id2, and E2F2 that were
upregulated and the Erythropoietin receptor (Epor), which
was dramatically downregulated (Figure 6B). The low level
of Epor is important given the defects previously observed in
‘stress’ erythropoiesis in the absence of Mtg16 (Chyla et al,
2008).
The levels of several key cell-cycle control genes were
consistently 2–4-fold higher than in control cells in either
microarray data or by QRT–PCR (Figure 6A and B).
Therefore, we used ChIP assays to determine whether any
of these genes are direct targets for regulation by Mtg16/Eto2.
We focused the ChIP assays towards regions of these genes
that are bound by factors that recruit MTG family members
including TCF4, E proteins, and CSL or that were identified by
overexpression of Mtg16 or Mtgr1 (Soler et al, 2010). While
we were unable to detect Mtg16 at the TCF4, E protein, or CSL
binding sites in the Cyclin D1 or N-Myc promoters in MEL
cells that express high levels of Mtg16 (Supplementary Figure
S6), we detected Mtg16 near an E2A binding motif in the first
intron of E2F2 (Lin et al, 2010), which we confirmed using
anti-E47 (Figure 6C). Mtg16/Eto2 localized to this site in E2F2
using two sets of primers (Figure 6C) and two additional
anti-Mtg16/ETO2 antibodies (Hunt, Engel, and Hiebert,
unpublished data). While negative data with ChIP does not
rule out the possibility that Mtg16 is required to suppress
Cyclin D1 or N-Myc or other regulators of the cell cycle, Mtg16
associates with E2F2, whose overexpression is sufficient to
drive quiescent cells into the S phase (DeGregori et al, 1997).
Mtg16 is required for maintaining stem cell quiescence
The upregulation of cell-cycle control genes suggested that
the exhaustion of stem cells after serial competitive trans-
plant of Mtg16/ BM could be due to inappropriate entry of
the stem cell population into the cell cycle. To test this
hypothesis, BrdU was injected into control and Mtg16/
mice to assess the number of LSK cells in the S phase of the
cell cycle. Two hours after injecting with BrdU, flow cyto-
metric analysis revealed that a higher portion of LSK cells
from Mtg16/ mice incorporated BrdU, as compared with
wild-type cells, indicating that more Mtg16-null stem and
early progenitor cells had entered the cell cycle (Figure 7A;
see Supplementary Figure S7A for further quantification).
Further analysis of the cell cycle was performed by flow
cytometry analysis of the incorporation of the DNA dye
Hoechst 33342 (HO) and RNA dye Pyronin Y (PY), which
identifies quiescent cells based on their lower output of RNA.
The lower percentage of Mtg16/ LSK cells that were
Hoechst and Pyronin low (G0 cells) compared with wild-
type mice indicated a loss of quiescent cells (Figure 7B; see
Supplementary Figure S7B for further quantification). Finally,
we examined the LSK/Flt3 and the LSK/CD150þ/CD48
long-term HSC compartments and found that in the absence
of Mtg16, nearly two third more LSK/Flt3 or LSK/CD150þ/
CD48 cells incorporated BrdU indicating that these cells
were in the cell cycle (Figure 7C and D; see Supplementary
Figure S7C and D for FACS plots). These data suggest that loss
of Mtg16 allowed stem cell entry into the cell cycle.
Both the methylcellulose serial replating and LTC-IC assays
suggest that the Mtg16-null stem/progenitor cells have de-
creased self-renewal potential and, together with the compe-
titive BM transplants, suggest that Mtg16 may have intrinsic
functions in the HSC. Therefore, we performed BrdU incor-
poration analysis on mice after competitive BM transplanta-
tion using 90% null cells and 10% wild type. Because the
yield of Mtg16/ cells is low after transplant (Figure 2), we
were only able to examine LSK cells (rather than LSK/Flt3).
Nevertheless, even in the presence of wild-type progenitor
cells that negate any Mtg16/ progenitor cell defects, the
Mtg16/ LSK population showed an increase in the percen-
tage of cycling cells, as compared with the control mice
containing wild-type CD45.2þ LSK cells (Figure 7E). These
results suggest that the increased cycling observed in the LSK
compartment was not due to downstream defects in progeni-
tor cells, but that Mtg16/Eto2 is required to suppress stem cell
entry into the cell cycle.
Discussion
In this study, we examined the role of Mtg16, a transcriptional
co-repressor, in HSC functions. Inactivation of Mtg16 reduced
HSC numbers, and more importantly, resulted in a loss of
self-renewal both in vivo and in vitro. This loss of self-
renewal and eventual stem cell exhaustion appeared to be
due to inappropriate entry of stem cells into the cell cycle.
One function of Mtg16 is to link DNA binding transcription
factors that control haematopoiesis to chromatin modifying
enzymes such as histone deacetylases. We found that E2F2, a
transcription factor that when overexpressed was sufficient to
drive quiescent fibroblasts into the cell cycle, was upregu-
lated in Mtg16/ LSK cells. In addition, Mtg16 robustly
associated with an enhancer-like sequence in the first intron
of E2F2, suggesting that E2F2 is a direct target for Mtg16-
mediated repression. However, this does not preclude Mtg16-
dependent regulation of other key regulators of the cell cycle.
Notably, N-Myc was consistently overexpressed in gene ex-
pression analysis of Mtg16/ cells (Chyla et al, 2008). Thus,
Mtg16/Eto2 is likely required to maintain control of a cell-
cycle regulatory circuit that when misregulated can drive
quiescent stem cells into DNA synthesis or prevent cycling
stem cells from entering G0 (DeGregori et al, 1997).
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The site in the E2F2 gene that was selected for ChIP was
based on ChIP-seq data linking E2A to this region (Lin et al,
2010) and we confirmed that E2A does associate with this
sequence (Figure 6C), suggesting that E2A or other E proteins
recruit Mtg16 to E2F2 to control entry of cells into the cell
cycle. The E proteins (e.g., E2A, E2-2, and HEB) belong to a
family of helix-loop-helix transcription factors that activate
transcription by binding to the ‘E-box’. These factors contain
two activation domains, and the most N-terminal activation
domain is also a key contact point for MTG/ETO family
members (Plevin et al, 2006; Guo et al, 2009; Park et al,
2009). The ability of E proteins to activate transcription is
modulated by the Id proteins as well as by TAL1/SCL
and related proteins. In proteomic analyses, MTG/ETO
family members have been found in complexes containing
E proteins, TAL1/SCL, Lmo2, Gfi1, GATA factors, other
transcriptional co-repressors, and Tif1g, which regulates
transcriptional elongation (McGhee et al, 2003; Schuh et al,
2005; Hamlett et al, 2008; Cai et al, 2009; Bai et al, 2010;
Fujiwara et al, 2010). While it is still unclear whether these
proteomic studies are detecting one large complex or several
smaller complexes, our results are consistent with Mtg16
acting as a co-repressor, perhaps by binding to E2A, such
that the inactivation of Mtg16 caused increased expression of
E2F2, as well as other cell-cycle control factors. It is notable
that the phenotypes that arise in mice engineered to delete
A
B
Mtg16-null  versus WT
Microarray RT–PCR
CcnD1 2.71 ± 0.23 2.25 ± 0.25
E2F2 2.39 ± 0.49 2.7 ± 0.1
GATA3 1.85 ± 0.03 2.0 ± 0.40
NC 0.125 ± 1.38
Id1
Gfi1
5.6 ± 2.54 4.85 ± 1.25
Id2 6.61 ± 0.65 5.15 ± 0.85
N-myc 2.6 ± 0.06 3.55 ± 0.45
EpoR –5.04 ± 3.27 –16.65 ± 6.65
C











Cyclin-dependent kinase 2 Cdk2 4.10
Cyclin G2 Ccng2 3.80
Janus kinase 2 Jak2 3.41
V-raf-leukaemia viral 
oncogene 1 Raf1 2.94
E2F transcription factor 2 E2F2 2.79
Cyclin D1 Ccnd1 2.70
Reticuloendotheliosis 
oncogene Rel 2.68
CDC14 cell division cycle 14 
homologue B (S. cerevisiae) Cdc14b 2.50
CDC14 cell division cycle 14 
homologue A (S. cerevisiae) Cdc14a 2.11
Polo-like kinase 4 
(Drosophila) Plk4 1.71
Cell division cycle 25 
homologue B (S. cerevisiae) Cdc25b 1.60
Gene name Gene symbol
Fold 
change
Retinoid X receptor alpha Rxra 0.63
Polymerase (DNA directed), 
delta 1, catalytic subunit Pold1 0.59
Polymerase (DNA directed), 
gamma Polg 0.53
Lethal(3)malignant brain 
tumour-like 2 (Drosophila) L3mbtl2 0.50
Cell division cycle 34 
homologue (S. cerevisiae) Cdc34 0.50
Checkpoint kinase 1 
homologue (S. pombe) Chek1 0.47
CDC23 (cell division cycle 
23, yeast, homologue) Cdc23 0.41
X-ray repair 
complementing defective 
repair in Chinese hamster 
cells 2 Xrcc2 0.38
Minichromosome 
Maintenance deficient 2
mitotin (S. cerevisiae) Mcm2 0.38






















































Figure 6 Mtg16-null LSK cells have altered gene expression patterns. (A) Gene expression profiling of mRNA from LSK cells isolated from
wild-type and Mtg16-null mice was analysed using cDNA microarrays. Panther ontology analysis was used to group genes into specific
biological processes and representative genes associated with cell-cycle control with their relative expression levels when Mtg16 is deleted are
shown. (B) Quantitative RT–PCR of selected genes was used to validate the microarray studies. (C) Mtg16 associates with the first intron of
E2F2. Chromatin immunoprecipitated with the either control IgG or anti-Mtg16/Eto2 from lysates of MEL cells was amplified with two sets of
primers (Set 1 and Set 2) that encompass an E2A binding site in the first intron of E2F2, or as a control, the 30 untranslated region (UTR) of E2F2
using quantitative PCR. Graph shows the level of signal relative to IgG set to ‘1’. The panel at the right shows ChIP using anti-E47 with the same
E2F2 first intron primers. The ethidium bromide-stained agarose gel shows a representative PCR stopped after 30 cycles; In., input; 1 and 2
designate the duplicate PCR samples from the ChIP reaction using primer set #2 flanking the E2A binding site.
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E2A (Semerad et al, 2009) are similar to the defects found in
the absence of Mtg16 in regards to loss of HSC numbers and
functions.
The defects we observed in Mtg16-null mice also closely
resembled the phenotype associated with the deletion of Lyl1,
a basic helix-loop-helix (bHLH) transcription factor that is
closely related to TAL1/SCL and that may also associate with
MTG/ETO family members (Capron et al, 2006; Bai et al,
2010). Although the Lyl1/mice displayed normal blood cell
counts with only a slight reduction in the number of B cells,
they too contain decreased numbers of LSK cells and LT-HSC
frequencies, which resulted in decreased function in CFU-S12
and LTC-IC assays. In accordance, Lyl-1-null BM was severely
impaired in its competitive repopulation abilities, especially
in the ability to reconstitute the B and T cell lineages (Capron
et al, 2006). However, the Lyl1-null BM did not recapitulate
the increased propensity towards myeloid development that
we observed in the absence of Mtg16. Given that Mtg16 is a
co-repressor that interacts with multiple transcription factors
and proteins, it is not surprising that its deletion would lead
to more pleiotropic effects than the deletion of a single
transcription factor. Taken together, these results highlight
the importance of Mtg16 as a master regulator of haemato-
poiesis as it orchestrates the action of multiple transcription
factors that are important for HSC functions in long-term self-
renewal and in lineage cell fate decisions.
In addition to the involvement of Mtg16 in haematopoietic
stem/progenitor cells, MTG family members may contribute
to the function of other types of stem and progenitor cells.
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Figure 7 Inactivation of Mtg16 leads to a decrease in the number of quiescent LSK cells. (A) Cell-cycle status of LSK cells was analysed using
BrdU. A representative FACS plot from an experiment performed with five mice that is consistent with other biological replicates is shown. (B)
Cell-cycle status of LSK cells was analysed with the DNA dye Hoechst 33342 (HO) and the RNA dye Pyronin Y (PY). A representative plot from
an experiment performed in triplicate that is consistent with other biological replicates is shown. (C) Quantification of the percentage of LSK/
Flt3 cells in S phase using BrdU incorporation as described in (A), but incorporating anti-Flt3. Data are expressed as mean±s.e.m. and are
consistent with other biological replicates. *An unpaired two-tailed t-test yielded Po0.0001; n¼ 6. (D) Quantification of the percentage of LSK/
CD150þ/CD48 cells in S phase using BrdU incorporation as described in (A). Data are expressed as mean±s.e.m. and are consistent with
other biological replicates. *An unpaired two-tailed t-test yielded P¼ 0.025; wild type, n¼ 7; Mtg16-null, n¼ 8. (E) Quantification of the
number of LSK cells in the S phase 5–6 weeks after competitive repopulation was analysed using BrdU as described in (A). Data are expressed
as mean±s.e.m. and are from biological replicates. *An unpaired two-tailed t-test yielded CD45.2þ , LSK BrdUþ , P¼ 0.0069; wild type, n¼ 4;
Mtg16-null, n¼ 8.
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lineage cells in the small intestine (Amann et al, 2005). After
treatment with the ulcerative agent dextran sodium sulphate,
which denudes the colonic epithelium, the Mtgr1-null colons
displayed bifide glands and loss of glands, suggesting a defect
in stem cell functions. These phenotypes were also associated
with inappropriate cycling of the stem/progenitor cells in the
crypts of the small intestine (Martinez et al, 2006). Gene
targeting studies of Mtg8 indicated that it is required for the
development of the murine gut as some pups died due to
deletion of the mid-gut (Calabi et al, 2001). In mice that
retained the mid-gut, there was a dramatic loss of architec-
ture, which could be due to defective stem cells. Thus, it is
possible that all three MTG/ETO family members function in
adult stem cells, perhaps to prevent entry into the cell cycle.
Our work may also hint of a role for MTG/ETO factors in
leukaemogenesis. Although little has been done with the
t(16;21), the t(8;21) is viewed as a relatively weak oncogene,
as patients can carry this translocation for several years
before developing AML (Peterson and Zhang, 2004).
However, in mouse models of t(8;21) AML, the oligomeriza-
tion domain, which also binds to endogenous Mtg16/Eto2
and Mtgr1, is essential to the transforming ability of the
fusion protein (Yan et al, 2004, 2009). Therefore, it is possible
that binding of the t(8;21) fusion protein to Mtg16 impairs
the action of Mtg16 and causes the HSC to enter the cell cycle.
In addition, the fusion protein can directly repress the
expression of tumour suppressors such as p14ARF,
Neurofibromatosis-1, PU.1, and C/EBPa (Pabst et al, 2001;
Linggi et al, 2002; Vangala et al, 2003; Yang et al, 2005).
These data suggest that the t(8;21) could promote immorta-
lization of haematopoietic stem and progenitor cells by
repressing tumour suppressor genes, while triggering prolif-
eration by activating genes such as E2F2.
Materials and methods
Mice
Mtg16-null mice were generated in our laboratory as previously
described (Chyla et al, 2008) and backcrossed for up to 10
generations with C57BL6 mice purchased from NCI/Charles Rivers.
Cell culture and expression analysis
OP9-GFP stromal cells were cultured in a-MEM (Gibco) supple-
mented with 20% heat-inactivated fetal bovine serum (FBS), 50 U/ml
penicillin, and 50mg/ml streptomycin. Bosc23 cells were cultured in
Dulbecco’s modified Eagle Medium (DMEM) supplemented with 10%
FBS, 50U/ml penicillin, 50mg/ml streptomycin, and 2mM L-gluta-
mine. Expression from MSCV-IRES-GFP plasmids was confirmed after
transfection of 3mg of plasmid into Bosc23 virus-producing cells with
PolyFect (Qiagen). Plasmid construction was previously described
(Hunt et al, 2011). At 48h post transfection, cells were harvested into
radioimmunoprecipitation assay (RIPA) buffer containing protease
inhibitors, diluted 1:2 in Laemmli’s sample buffer (Bio-Rad), sonicated,
and subjected to 10% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis. Immunoblot analyses were performed using anti-Myc
9E10 antibody, with actin expression (Sigma) as a loading control.
Expressed proteins were visualized using fluorophore-conjugated
secondary antibodies and the Odyssey system (LiCor).
Flow cytometry analysis
Single cell suspensions were obtained by flushing the tibia and
femur. Following treatment with erythrocyte lysis buffer, the
remaining cells were stained with antibodies against: CD3, Ter119,
Gr1, Mac1, B220, ScaI, c-Kit, CD45.1, CD45.2, Flt3, CD150, or CD48.
Analysis was performed on a Becton Dickinson FACSCalibur or
LSRII flow cytometer. To assess the cell-cycle status of the LSK cells,
BM cells were resuspended in RPMI with 10% FBS and incubated
with 10 mg/ml of Hoechst 33342 (Invitrogen) for 45 min at 371C,
washed and incubated with the indicated antibodies. Finally, the
cells were fixed overnight at 41C in 5% paraformaldehyde in PBS
and incubated with 0.5mM Pyronin Y (Polysciences, Inc.) for 30 min
on ice prior to analysis. For the BrdU incorporation assays, mice
were sacrificed 2 hours after intraperitoneal injection of 1 mg of
BrdU. Cells were then harvested as previously described and
labelled following the instructions of the BrdU Flow Kit (BD
Pharmingen).
Microarray and real-time quantitative PCR
BM cells were harvested and the lineage-negative fraction was
separated using the Lineage Cell Depletion Kit and MACS columns
(Miltenyi Biotec). The lineage-negative fraction was then stained
with antibodies for flow cytometry and the LSK cells were sorted on
a Becton Dickinson FACSAria. Total RNA was extracted using the
Versagene Total RNA Purification Kit (Gentra Systems) and
microarray analysis was performed with the Applied Biosystem
Inc. expression system. Probes with a signal-to-noise ratio of greater
than 3 ranged from 43 to 50% of total probes. Quantile normal-
ization was done using ABarray R script. Q-normalized data were
put into GeneSpring to make comparisons. Probes without an SN
greater than 3 in at least two of the five samples were excluded from
the analysis. The microarray data were analysed using the Panther
classification system for gene ontology classes based upon
biological processes (Thomas et al, 2003). A P-value was calculated
using the Mann–Whitney U-test (Wilcoxon Rank-Sum test) for each
classification and the cell-cycle gene classification P-value using
genes with at least 1.5-fold change was 0.006, and 0.05 using a two-
fold change in null versus wild-type RNA. For the quantitative PCR,
1mg of total RNA was transcribed with the iScript cDNA Synthesis
kit (Bio-Rad) and 1/10 of the reaction was used for PCR using
TaqMan primers on an automated ABI platform. PCRs were
performed in triplicate. The expression of the gene of interest was
calculated relative to the levels of GusB. Primer sequences were
selected from the PrimerBank database (Wang and Seed, 2003). The
gene expression of the MTG family members in the fibroblast cells
was performed as previously described (Hunt et al, 2011).
Stem cell and progenitor cell assays
To perform the methylcellulose serial replating assays, we harvested
BM and plated 2104 total BM cells in methylcellulose media
(Methocult GF M3434; Stem Cell Technologies). Every 7 days for 4
weeks, the numbers of colonies was counted, the plates were
harvested, and 2104 cells were replated in methylcellulose media.
For the LTC-IC assay, 3103 lineage-negative cells were cultured on
OP9 stromal cells in a 96-well plate at 331C and 5% CO2 and weekly
semi-replenishment of media (MyeloCultTM M5300 with 106 M
hydrocortisone, Stem Cell Technologies) was performed (see Stem
Cell Technologies website for a detailed protocol). At 1-week
intervals, a set of wells was harvested and the cells were plated in
methylcellulose media (Methocult GF M3434; Stem Cell Technolo-
gies) and cultured for 10 days to determine the percentage of
positive wells (positive well scored with X1 colony).
For Mtg16 re-expression in the LTC-IC assay, MSCV-myc-Eto2-GFP
and variants (F210A and R220A) were transfected into Bosc23 virus-
producing cells. The viral supernatant was collected at 48 h post
transfection and filtered through a 45-mm syringe filter (Nalgene).
Lineage-negative cells were centrifuged at 1500 r.p.m. for 1 h at
room temperature with the viral supernatant prior to co-culture
with OP9-GFP stromal cells and carried out as normal for the LTC-IC
assay. Infection was monitored using flow cytometry to detect green
fluorescent protein (GFP) expression from an aliquot of cells that
were expanded for 5 days on OP9 stromal cells in RPMI
supplemented with 10% heat-inactivated FBS, 50 U/ml penicillin,
50mg/ml streptomycin, 5 ng/ml interleukin-6 (IL-6; Peprotech),
50 ng/ml stem cell factor (SCF; Peprotech) and 103 U/ml leukaemia
inhibitory factor (LIF; Chemicon).
For BM transplantation, a single cell suspension of BM cells was
obtained from the tibia and femur, and the red blood cells were
lysed with erythrocyte lysis buffer (Buffer EL, Qiagen). BM cells
were injected via the tail vein into lethally irradiated (900 rads)
recipient wild-type C57Bl/6 mice. For competitive reconstitution
assays, lethally irradiated C57Bl/6 CD45.1 congenic mice were used
as recipients. The Mtg16þ /þ or Mtg16-null donor cells were mixed
with C57Bl/6 CD45.1 BM cells (9:1). Reconstitution potential of the
donor (CD45.2) cells was monitored by flow cytometry of the peri-
pheral blood and BM. For the secondary competitive repopulation
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transplants, the BM was harvested as described 12 weeks after the
primary competitive transplant, and 2106 total BM cells were
injected into the tail vein of lethally irradiated recipients.
To assess total BM cell homing, we used the vital dye
carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes,
Inc.), as previously described (Chyla et al, 2008). To assess
progenitor cell homing, donor BM (WT or Mtg16-null) was
harvested and prepared as described for the BM transplants. In
all, 1107 cells were injected via the tail vein into lethally irradiated
recipient wild-type C57Bl/6 mice and an aliquot was also plated in
methylcellulose culture to quantify the input number of committed
progenitor cells. Sixteen hours later, the recipient mice were
euthanized and the cells from the femur and tibia were harvested.
Single-cell suspensions of the marrow cells were cultured in
triplicate to assess the donor output colony-forming units in the
recipient animals. For estimating total BM recovery, the femur/tibia
content was assumed to represent 9% of total BM (Boggs, 1984).
ChIP assays
ChIP assays were performed using MEL cells. In all, 1107 cells per
condition were crosslinked with 1% formaldehyde (Sigma) for
20 min and the crosslinking reaction was quenched by the addition
of glycine to a final concentration of 125 mM for 5 min. Cells were
collected, washed, and resuspended in a low salt ChIP buffer
(50 mM HEPES KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA pH 8.0, 1%
Triton X-100, and 0.1% Sodium Deoxycholate). Samples were
sonicated and cleared by centrifugation, then precleared with the
addition of Protein G Sepharose 4B (Sigma). Samples were
incubated overnight with Goat IgG (Santa Cruz), anti-Eto2 G20
(Santa Cruz), anti-E47 SC-763x (Santa Cruz), or Rabbit IgG control
(Millipore). Immune complexes were collected by incubation with
Protein G Sepharose 4B (Sigma) then washed with a low salt ChIP
buffer, a high salt ChIP buffer (50 mM HEPES KOH pH 7.5, 500 mM
NaCl, 1 mM EDTA pH 8.0, 1% Triton X-100, and 0.1% Sodium
Deoxycholate) and Lithium Chloride/NP-40 buffer (10 mM TrisCl,
pH 8.0, 250 mM LiCl, 0.5% NP-40, 0.5% Sodium Deoxycholate).
DNA–antibody complexes were eluted with elution buffer (1% SDS
and 100 mM Sodium Bicarbonate) and the crosslink was reversed
with 200 mM NaCl at 651C. DNA was precipitated with the addition
of 100% EtOH, RNase treated, Proteinase K (Sigma) treated, and
isolated using the Qiagen PCR Purification kit. RT–PCR was
performed with 2ml of each sample in duplicate using SybrGreen
(BioRad) and the BioRad ICycler and normalized to input. Primer
sequences are as follows: E2F2 Intron 1: F-50-GGACTCTGGAGGGCT
AATGTTG-30 R-50-GCAATGTCTTCACTCGGCTCGG-30; E2F2 Intron 2:
F-50TCAGACAGATGAGCGGGGAGGTG-30 R-50-GCCTCTGCCAGCCGC
TTGAAA-30; E2F2 30 UTR F-50-TGGTTTCCCCTCCCTGTGAGGC-30 R-
50-AGACCTGTAGCCACCACGGTCC-30; CCND1 TCF F-50-CTGCCCGG
CTTTGATCTCT-30 R-50-AGGACTTTGCAACTTCAACAAAACT-30; CCND1
EBox/CSL F-50-CTGGTCTGGCATCTTCGG-30 R-50-GAGAATGGGTGC




Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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